Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yasuhiro Oki

Showing results (71-80 of 164) with videos related to

Pageof 17
Sort By:
British Journal of Haematology|August 4, 2017
Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitorsPreetesh Jain, Rashmi Kanagal-Shamanna, F Anthony San Lucas, et al.
Leukemia & Lymphoma|April 27, 2018
Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure<sup/>Ethan B Ludmir, Sarah A Milgrom, Chelsea C Pinnix, et al.
Advances in Radiation Oncology|November 9, 2017
Effectiveness of low-dose radiation for primary cutaneous anaplastic large cell lymphomaGrace L Smith, Madeleine Duvic, Zeinab Abou Yehia, et al.
European Journal of Haematology|January 1, 2017
Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCHBeenu Thakral, L Jeffrey Medeiros, Parth Desai, et al.
American Journal of Hematology|July 24, 2018
Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 studyIan W Flinn, Manish Patel, Yasuhiro Oki, et al.
Experimental Hematology & Oncology|February 19, 2021
Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphomaPatrick B Johnston, Amanda F Cashen, Petros G Nikolinakos, et al.
International Journal of Radiation Oncology, Biology, Physics|March 11, 2015
Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphomaRanda Tao, Pamela K Allen, Alma Rodriguez, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 15, 2016
P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphomaXuan J Wang, L Jeffrey Medeiros, Carlos E Bueso-Ramos, et al.
Advances in Radiation Oncology|November 9, 2017
Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisionsChelsea C Pinnix, Therese Y Andraos, Bouthaina Dabaja, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 23, 2009
Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphomaMichael Wang, Yasuhiro Oki, Barbara Pro, et al.
Pageof 17

Showing results (71-80 of 164) with videos related to

Sort By:
Pageof 17
British Journal of Haematology|August 4, 2017
Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitorsPreetesh Jain, Rashmi Kanagal-Shamanna, F Anthony San Lucas, et al.
Leukemia & Lymphoma|April 27, 2018
Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure<sup/>Ethan B Ludmir, Sarah A Milgrom, Chelsea C Pinnix, et al.
Advances in Radiation Oncology|November 9, 2017
Effectiveness of low-dose radiation for primary cutaneous anaplastic large cell lymphomaGrace L Smith, Madeleine Duvic, Zeinab Abou Yehia, et al.
European Journal of Haematology|January 1, 2017
Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCHBeenu Thakral, L Jeffrey Medeiros, Parth Desai, et al.
American Journal of Hematology|July 24, 2018
Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 studyIan W Flinn, Manish Patel, Yasuhiro Oki, et al.
Experimental Hematology & Oncology|February 19, 2021
Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphomaPatrick B Johnston, Amanda F Cashen, Petros G Nikolinakos, et al.
International Journal of Radiation Oncology, Biology, Physics|March 11, 2015
Benefit of consolidative radiation therapy for primary bone diffuse large B-cell lymphomaRanda Tao, Pamela K Allen, Alma Rodriguez, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|October 15, 2016
P53 expression correlates with poorer survival and augments the negative prognostic effect of MYC rearrangement, expression or concurrent MYC/BCL2 expression in diffuse large B-cell lymphomaXuan J Wang, L Jeffrey Medeiros, Carlos E Bueso-Ramos, et al.
Advances in Radiation Oncology|November 9, 2017
Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisionsChelsea C Pinnix, Therese Y Andraos, Bouthaina Dabaja, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 23, 2009
Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphomaMichael Wang, Yasuhiro Oki, Barbara Pro, et al.
Pageof 17